Stock IMM IMMUTEP LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News Immutep Limited

Equities

IMM

AU000000IMM6

Delayed Australian S.E.
Other stock markets
 12:05:29 2024-04-30 am EDT 		5-day change 1st Jan Change
0.425 AUD -4.49% Intraday chart for Immutep Limited +10.39% +23.19%
03:03am Canaccord Starts Immutep at Buy, Price Target is AU$1.00 MT
Apr. 24 Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Canaccord Starts Immutep at Buy, Price Target is AU$1.00
MT
Immutep Quarterly Activities Report Q3 FY24
AQ
Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck
MT
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
CI
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761
AQ
Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761
CI
Wilsons - Adding Autoimmune to the indication list; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)
PU
Immutep Taps Center for Human Drug Research for IMP761 Human Clinical Trial
MT
Immutep : Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP76
PU
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
AQ
Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
CI
Australian Shares Tick Down as US Fed Chair Flags Likely Rate Cut Delay
MT
Immutep Obtains Support from Spanish Health Agency for Efti Registrational Trial
MT
Immutep : Corporate Presentation
PU
Encouraging results for Immutep's cancer therapies
FI
Ladenburg Thalmann - Next Is Dose Optimization for BC Program; Reiterate Buy, $8.30 PT (Analyst: Ahu Demir, PhD)
PU
Wilsons - Dose it higher? Now an option; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)
PU
Immutep Announces First Clinical Data from 90mg Dosing of Efti
AQ
Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti
CI
Immutep Posts 59% Rise in H1 FY24 Revenue, Narrows Net Loss
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMM Stock
  4. News Immutep Limited